DUBLIN, IRELAND--(Marketwire - January 24, 2008) - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the launch of its new Lyme Enzyme Immunoassay (EIA) products specifically designed for the European market.
